Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Alexandra M LevineLauri Welles

Abstract

To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL). Secondary objectives were to assess the impact of HIV viral control on response and survival, and to correlate MDR-1 expression with outcome. Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/m(2) was given with fixed doses of cyclophosphamide, vincristine, and prednisone every 21 days. All patients received concurrent highly active antiretroviral therapy. NHL tissues were evaluated for multidrug resistance (MDR-1) expression. Twenty-four patients were accrued. 67% had high or high-intermediate International Prognostic Index scores; the median CD4 lymphocyte count was 112/mm(3) (range, 19/mm(3) to 791/mm(3)). No dose-limiting toxicities were observed at any level, with myelosuppression being the most frequent toxicity. Overall response rate was 88%, with 75% complete responses (CRs), and 13% partial responses. The median duration of CR was 15.6+ months (range, 1.7 to 43.5+ months). Effective HIV viral control during chemotherapy was asso...Continue Reading

References

Dec 16, 1992·Journal of the National Cancer Institute·A RahmanR I Glazer
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T P MillerS E Salmon
Jan 1, 1991·Annual Review of Medicine·I Pastan, M M Gottesman
Dec 30, 1986·Biochemical and Biophysical Research Communications·K UedaJ R Riordan
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M HorioI Pastan
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A R Yuen, B I Sikic
Apr 1, 1993·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A R ThierryA Rahman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·B A ConleyD A Van Echo
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E VaccherA Carbone
Nov 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoJ P Dutcher
Feb 7, 1998·The Journal of Clinical Investigation·R B KimG R Wilkinson
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L RatnerUNKNOWN AIDS Malignancy Consortium
Jan 5, 2002·Leukemia Research·Anil TulpuleAlexandra M Levine
Jul 11, 2003·Lancet·A MocroftUNKNOWN EuroSIDA study group

❮ Previous
Next ❯

Citations

Apr 13, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Aleksander SochanikStanisław Szala
Aug 12, 2005·Current Opinion in Oncology·Anil Tulpule
Dec 25, 2008·Current Opinion in Oncology·Alexandra M Levine
Oct 13, 2004·Neuroendocrinology·Dermot O'ToolePhilippe Ruszniewski
Feb 26, 2010·Blood·Weihsu C ChenJames C Paulson
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra M LevineAnil Tulpule
Jan 1, 2009·Critical Reviews in Therapeutic Drug Carrier Systems·Anu PuriRobert Blumenthal
May 16, 2012·Hematology Reports·Stefano LuminariMassimo Federico
Jun 23, 2009·Malawi Medical Journal : the Journal of Medical Association of Malawi·Emma CrutchlowTom Latham
Sep 11, 2013·North American Journal of Medical Sciences·Nagesh Tatero SirsathGovind Babu Kanaka Setty
Nov 22, 2014·Nanomedicine·Giuseppe VisaniAlessandro Isidori
Mar 9, 2012·Advances in Hematology·Prakash Vishnu, David M Aboulafia
Jun 24, 2008·Leukemia & Lymphoma·Giuseppe VisaniAlessandro Isidori
Sep 25, 2015·Expert Review of Anticancer Therapy·Edouard AlphandéryMickael Durand-Dubief
Mar 12, 2009·Expert Review of Anticancer Therapy·Giuseppe Visani, Alessandro Isidori
Mar 1, 2006·Expert Review of Anticancer Therapy·Danish MazharMark Bower
Aug 4, 2009·Expert Opinion on Biological Therapy·Thomas Newsom-DavisMark Bower
Sep 24, 2013·Expert Opinion on Drug Metabolism & Toxicology·Ana Espirito Santo, Rui Medeiros
Jan 19, 2007·British Journal of Haematology·Nicolas MounierChristian Gisselbrecht
Oct 11, 2016·Expert Review of Gastroenterology & Hepatology·Elisabetta DegasperiAlessio Aghemo
May 11, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soon Thye LimAlexandra M Levine
Oct 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soon-Thye LimAlexandra M Levine
Dec 13, 2005·Expert Review of Anticancer Therapy·Hashim Uddin AhmedHitendra R H Patel
Nov 10, 2006·American Journal of Hematology·George PanosMatthew E Falagas
Feb 3, 2018·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Rajiv PanwarBan An Khaw
Nov 15, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Scott R PenzakJoseph Kovacs
Dec 24, 2005·Current Opinion in Infectious Diseases·Mark BowerTony Dhillon
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalAble Lawrence
Jan 3, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Chalid AssafRudolf Stadler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.